Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2019

View Archived Issues

TNFR2 is yang to TNFR1's yin

IL-13Rlalpha2 as a therapeutic target in inflammatory bowel disease

Adropin is correlated with erectile dysfunction in coronary artery disease patients

Fast skeletal muscle troponin activators can counter skeletal muscle fatigue

Triple kinase inhibitor IBL-302 shows promising activity in preclinical models of neuroblastoma

New sialyltransferase inhibitors synthesized at Radboud Universiteit Nijmegen

InnoCare Pharma patents indoleamine 2,3-dioxygenase 1 inhibitors

Initiator Pharma provides an update on IPED-2015 and IP-2018 development

Anti-LAG-3 fully human innovative antibody LBL-007 receives clinical approval

Decrease in tumor biomarkers seen in AIVITA's phase II study in patients with glioblastoma

Gritstone Oncology initiates phase I/II study of neoantigen-based therapeutic cancer vaccine

Positive topline results presented from ELIPSE HoFH phase III study of evinacumab

Themis Bioscience recruiting participants in phase I study of MV-ZIKA-RSP vaccine

H3R inverse agonist LML-134 demonstrates rapid brain penetration and fast kinetic profile

Pharmacokinetics and safety data presented from phase I study of EA-230

Sunshine Lake Pharma discovers sodium/glucose cotransporter 1 inhibitors

New dopamine D3 receptor antagonists synthesized at Shionogi

Cadila Healthcare identifies bacterial DNA topoisomerase II inhibitors

FDA approves new drug combination for highly drug-resistant tuberculosis

Rozlytrek approved by FDA or two new cancer indications

CARB-X awards funding to IBT to expand development of its IBT-V02 vaccine

Helmholtz Zentrum Munchen, Phio to identify new targets based on sd-rxRNA platform

CytoDyn provides update on its HIV dose-escalating monotherapy trial of leronlimab

Soligenix awarded grant to evaluate SGX-942 in pediatric indications

In dopamine D1 receptor combo, ghrelin is resurrected as Alzheimer's target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...